Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy

ABSTRACT

Introduction

DBV712 250 µg (also referred to as Viaskin Peanut or peanut patch; Viaskin is a trademark of DBV Technologies) is an innovative approach to epicutaneous immunotherapy (EPIT). The patch-based technology system facilitates peanut protein (allergen) absorption into the intact non-vascularized epidermis to promote desensitization to peanut while limiting systemic allergen exposure.

Areas Covered

Efficacy and safety in children have been evaluated in four completed phase 3 studies. Overall, the results from these studies have demonstrated the peanut patch to be superior in desensitization compared with placebo and safe for daily use over multiple years.

Expert Opinion

These findings, as well as supportive evidence from phase 2 studies, confirm the potential for an effective treatment of peanut allergy in children. The purpose of this review is to summarize the safety and efficacy of the peanut patch in the treatment of peanut allergy.

GRAPHICAL ABSTRACT

KEYWORDS:

• Desensitization
• epicutaneous immunotherapy
• food allergy
• peanut allergy
• arachis hypogaea
• skin patch
• Viaskin Peanut
• children

Article highlights

• EPIT with the peanut patch demonstrated superior desensitization to peanut compared to placebo in peanut-allergic children.

• Increases in eliciting dose and cumulative reactive dose to peanut after 12 months with further benefits out to 3 years of treatment in children.

• Reduced severity of reactions to peanut during food challenges after 12 months of treatment with the peanut patch.

• Consistent safety profile across studies, with mainly mild-to-moderate local application site reactions.

• Participants reported high compliance with treatment and low discontinuations due to adverse events.

Declaration of interests

C Dupont reports being a co-founder and shareholder of DBV Technologies, receives consulting fees from Nestlé, Danone, BMS, and lecture fees from Novalac, Mead Johson. D Fleischer provides research support to institution from DBV Technologies and is a consultant for DBV Technologies. A Burks reports consulting fees from Allergy Therapeutics, Aimmune Therapeutics, Consortia TX, DBV Technologies, Ukko, grants to his institution from Burroughs Wellcome Fund, research grant from the National Institute of Health, and royalties from UpToDate. K Bee and S Chainani are employees of DBV Technologies. H Sampson reports consulting fees from N-Fold, LLC, DBV Technologies, Abbvie, and Siolta Therapeutics, grants to his institution from the National Institute of Allergy and Infectious Diseases and from Allergenis, and royalties from Elsevier. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

One reviewer is a co-founder of Saiba AG. The remaining reviewers have no other relevant financial relationships or otherwise to disclose.

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/1744666X.2024.2315221

Additional information

Funding

This manuscript was funded by DBV Technologies.